{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T21:04:38Z","timestamp":1790197478397,"version":"4.1.0"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T00:00:00Z","timestamp":1786320000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","esmoiotech.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Immuno-Oncology and Technology"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.iotech.2026.101613","type":"journal-article","created":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T17:59:14Z","timestamp":1789667954000},"page":"101613","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Quality of life and care experience in durable responders to immune checkpoint inhibitors for advanced or metastatic NSCLC or melanoma"],"prefix":"10.1016","volume":"32","author":[{"given":"N.","family":"Girard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Bonastre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Spurrier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9656-2432","authenticated-orcid":false,"given":"H.","family":"Lemasson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Chartier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-2972-1664","authenticated-orcid":false,"given":"V.","family":"Moreau Mallet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Michelliza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3749-254X","authenticated-orcid":false,"given":"N.","family":"Texier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Hervy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Robert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.iotech.2026.101613_bib1","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1158\/1078-0432.CCR-18-0793","article-title":"Long-term survival in patients responding to anti-PD-1\/PD-L1 therapy and disease outcome upon treatment discontinuation","volume":"25","author":"Gauci","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"12","key":"10.1016\/j.iotech.2026.101613_bib2","doi-asserted-by":"crossref","first-page":"2849","DOI":"10.1158\/1078-0432.CCR-19-3418","article-title":"Circulating tumor DNA analysis to assess risk of progression after long-term response to PD-(L)1 blockade in NSCLC","volume":"26","author":"Hellmann","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.iotech.2026.101613_bib3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.18.00114","article-title":"Comparative analysis of durable responses on immune checkpoint inhibitors versus other systemic therapies: a pooled analysis of phase III trials","volume":"3","author":"Pons-Tostivint","year":"2019","journal-title":"JCO Precis Oncol"},{"issue":"3","key":"10.1016\/j.iotech.2026.101613_bib5","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.jtho.2018.11.019","article-title":"Quality of life in NSCLC survivors - a multicenter cross-sectional study","volume":"14","author":"Hechtner","year":"2019","journal-title":"J Thorac Oncol"},{"issue":"7","key":"10.1016\/j.iotech.2026.101613_bib6","first-page":"3267","article-title":"Health-related quality of life, emotional burden, and neurocognitive function in the first generation of metastatic melanoma survivors treated with pembrolizumab: a longitudinal pilot study","volume":"28","author":"Rogiers","year":"2020","journal-title":"Support Care Cancer"},{"issue":"1","key":"10.1016\/j.iotech.2026.101613_bib7","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2019-000260","article-title":"Quality of life in long-term survivors of advanced melanoma treated with checkpoint inhibitors","volume":"8","author":"Mamoor","year":"2020","journal-title":"J Immunother Cancer"},{"issue":"2","key":"10.1016\/j.iotech.2026.101613_bib8","first-page":"561","article-title":"An immunotherapy survivor population: health-related quality of life and toxicity in patients with metastatic melanoma treated with immune checkpoint inhibitors","volume":"28","author":"O\u2019Reilly","year":"2020","journal-title":"Support Care Cancer"},{"issue":"4","key":"10.1016\/j.iotech.2026.101613_bib9","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.6872","article-title":"Unmet needs, quality of life, and financial toxicity among survivors of lung cancer","volume":"7","author":"Hsu","year":"2024","journal-title":"JAMA Netw Open"},{"issue":"4","key":"10.1016\/j.iotech.2026.101613_bib10","doi-asserted-by":"crossref","first-page":"785","DOI":"10.21037\/tlcr-23-815","article-title":"Carrying on with life as a lung cancer survivor: a qualitative study of Australian survivors' employment, finances, relationships, and healthcare experiences","volume":"13","author":"Laidsaar-Powell","year":"2024","journal-title":"Transl Lung Cancer Res"},{"key":"10.1016\/j.iotech.2026.101613_bib11","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.lungcan.2019.03.010","article-title":"Lung cancer survivors and employment: a systematic review","volume":"131","author":"Vayr","year":"2019","journal-title":"Lung Cancer"},{"key":"10.1016\/j.iotech.2026.101613_bib12","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.ejca.2020.05.005","article-title":"Survivorship in immune therapy: assessing toxicities, body composition and health-related quality of life among long-term survivors treated with antibodies to programmed death-1 receptor and its ligand","volume":"135","author":"Patrinely","year":"2020","journal-title":"Eur J Cancer"},{"issue":"4","key":"10.1016\/j.iotech.2026.101613_bib13","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1038\/s41571-022-00600-w","article-title":"Immune-checkpoint inhibitors: long-term implications of toxicity","volume":"19","author":"Johnson","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"issue":"24","key":"10.1016\/j.iotech.2026.101613_bib14","doi-asserted-by":"crossref","first-page":"3917","DOI":"10.3390\/cancers17243917","article-title":"Health-related quality of life in the era of immune checkpoint blockade: what do patient-reported outcomes reveal?","volume":"17","author":"Dunker","year":"2025","journal-title":"Cancers (Basel)"},{"issue":"4","key":"10.1016\/j.iotech.2026.101613_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2021.100239","article-title":"Management of lung cancer patients\u2019 quality of life in clinical practice: a Delphi study","volume":"6","author":"Westeel","year":"2021","journal-title":"ESMO Open"},{"issue":"1","key":"10.1016\/j.iotech.2026.101613_bib16","doi-asserted-by":"crossref","DOI":"10.2196\/25792","article-title":"Integrating quality of life in the care pathway of cancer patients undergoing immunotherapy treatment: descriptive, cross-sectional survey of an online patient community\u2019s experiences and expectations","volume":"11;24","author":"Wilczynski","year":"2022","journal-title":"J Med Internet Res"},{"issue":"10","key":"10.1016\/j.iotech.2026.101613_bib17","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1007\/s11136-011-9903-x","article-title":"Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L)","volume":"20","author":"Herdman","year":"2011","journal-title":"Qual Life Res"},{"issue":"1","key":"10.1016\/j.iotech.2026.101613_bib18","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1186\/s12955-024-02294-3","article-title":"Estimating the minimally important difference for the EQ-5D-5L and EORTC QLQ-C30 in cancer","volume":"22","author":"Bourke","year":"2024","journal-title":"Health Qual Life Outcomes"},{"issue":"2","key":"10.1016\/j.iotech.2026.101613_bib19","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1007\/s11136-004-5332-4","article-title":"Development and evaluation of an instrument to assess social difficulties in routine oncology practice","volume":"14","author":"Wright","year":"2005","journal-title":"Qual Life Res"},{"issue":"11","key":"10.1016\/j.iotech.2026.101613_bib20","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1016\/j.ejca.2008.04.011","article-title":"Measurement and interpretation of social distress using the social difficulties inventory (SDI)","volume":"44","author":"Wright","year":"2008","journal-title":"Eur J Cancer"},{"issue":"2","key":"10.1016\/j.iotech.2026.101613_bib21","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/0022-3999(93)90081-P","article-title":"Development of a fatigue scale","volume":"37","author":"Chalder","year":"1993","journal-title":"J Psychosom Res"},{"issue":"11","key":"10.1016\/j.iotech.2026.101613_bib22","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1002\/pon.4368","article-title":"Health-related quality of life in cancer survivorship: predictive power of the Social Difficulties Inventory","volume":"26","author":"Ashley","year":"2017","journal-title":"Psychooncology"},{"issue":"11","key":"10.1016\/j.iotech.2026.101613_bib23","doi-asserted-by":"crossref","first-page":"12861","DOI":"10.1002\/cam4.5967","article-title":"Health-related quality of life in survivors of advanced melanoma treated with anti-PD1-based immune checkpoint inhibitors","volume":"12","author":"Looman","year":"2023","journal-title":"Cancer Med"},{"issue":"1","key":"10.1016\/j.iotech.2026.101613_bib24","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1080\/0284186X.2020.1818823","article-title":"Health-related quality of life of long-term advanced melanoma survivors treated with anti-CTLA-4 immune checkpoint inhibition compared to matched controls","volume":"60","author":"Boekhout","year":"2021","journal-title":"Acta Oncol"},{"issue":"9","key":"10.1016\/j.iotech.2026.101613_bib25","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1007\/s10198-022-01559-2","article-title":"Population norms in France with EQ-5D-5L: health states, value indexes, and VAS","volume":"24","author":"Gautier","year":"2023","journal-title":"Eur J Health Econ"},{"issue":"5","key":"10.1016\/j.iotech.2026.101613_bib26","first-page":"322","article-title":"Lung cancer-specific symptoms and fear of cancer recurrence among recurrence-free non-small cell lung cancer survivors","volume":"32","author":"Lee","year":"2024","journal-title":"Support Care Cancer"},{"issue":"3","key":"10.1016\/j.iotech.2026.101613_bib27","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1111\/bjd.21670","article-title":"Experiences of resuming life after immunotherapy and associated survivorship care needs: a qualitative study among patients with metastatic melanoma","volume":"187","author":"Kamminga","year":"2022","journal-title":"Br J Dermatol"},{"issue":"1","key":"10.1016\/j.iotech.2026.101613_bib28","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1186\/s12885-024-12410-7","article-title":"From decision to reflection: understanding the experiences and unmet care needs of patients treated with immunotherapy for melanoma in the adjuvant or metastatic setting","volume":"24","author":"Kamminga","year":"2024","journal-title":"BMC Cancer"},{"issue":"4","key":"10.1016\/j.iotech.2026.101613_bib29","first-page":"222","article-title":"What patients with advanced cancer experience as helpful in navigating their life with a long-term response: a qualitative study","volume":"32","author":"Zwanenburg","year":"2024","journal-title":"Support Care Cancer"},{"issue":"1","key":"10.1016\/j.iotech.2026.101613_bib30","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa2407417","article-title":"Final, 10-year outcomes with nivolumab plus ipilimumab in advanced melanoma","volume":"392","author":"Wolchok","year":"2025","journal-title":"N Engl J Med"}],"container-title":["Immuno-Oncology and Technology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590018826000328?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590018826000328?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T20:25:16Z","timestamp":1790195116000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2590018826000328"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":29,"alternative-id":["S2590018826000328"],"URL":"https:\/\/doi.org\/10.1016\/j.iotech.2026.101613","relation":{},"ISSN":["2590-0188"],"issn-type":[{"value":"2590-0188","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Quality of life and care experience in durable responders to immune checkpoint inhibitors for advanced or metastatic NSCLC or melanoma","name":"articletitle","label":"Article Title"},{"value":"Immuno-Oncology and Technology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.iotech.2026.101613","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"101613"}}